Cargando…

COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases

Detalles Bibliográficos
Autores principales:	Boekel, Laura, Hooijberg, Femke, Besten, Yaëlle R, Vogelzang, Erik H, Steenhuis, Maurice, Leeuw, Maureen, Atiqi, Sadaf, van Vollenhoven, Ronald, Lems, Willem F, Bos, Wouter H, Wijbrandts, Carla A, Gerritsen, Martijn, Krieckaert, Charlotte, Voskuyl, Alexandre E, van der Horst-Bruinsma, Irene E, Tas, Sander W, Boers, Maarten, Rispens, Theo, Nurmohamed, Michael T, Wolbink, Gertjan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824534/ https://www.ncbi.nlm.nih.gov/pubmed/35156061 http://dx.doi.org/10.1016/S2665-9913(22)00009-1

Ejemplares similares

Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands
por: Boekel, Laura, et al.
Publicado: (2023)

SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period
por: Boekel, Laura, et al.
Publicado: (2022)

Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population
por: Hooijberg, Femke, et al.
Publicado: (2020)

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
por: Boekel, Laura, et al.
Publicado: (2022)

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2021)

Immunogenicity of TNF-Inhibitors
por: Atiqi, Sadaf, et al.
Publicado: (2020)

Perspective of patients with autoimmune diseases on COVID-19 vaccination
por: Boekel, Laura, et al.
Publicado: (2021)

Adverse events after first COVID-19 vaccination in patients with autoimmune diseases
por: Boekel, Laura, et al.
Publicado: (2021)

Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial
por: Wientjes, Maike H. M., et al.
Publicado: (2021)

Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic
por: Boekel, L., et al.
Publicado: (2021)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated
por: Raadsen, Reinder, et al.
Publicado: (2023)

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review
por: Krieckaert, Charlotte Louise Maria, et al.
Publicado: (2010)

Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up
por: Vogelzang, E. H., et al.
Publicado: (2018)

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
por: Boekel, Laura, et al.
Publicado: (2022)

Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study
por: van Sijl, Alper M., et al.
Publicado: (2014)

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab
por: de Jong, Tamarah D, et al.
Publicado: (2015)

A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks
por: den Uyl, Debby, et al.
Publicado: (2014)

Are we ready for therapeutic drug monitoring of biologic therapeutics?
por: Krieckaert, Charlotte LM, et al.
Publicado: (2011)

Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
por: van Vollenhoven, Ronald F, et al.
Publicado: (2023)

A neutrophil signature is strongly associated with increased cardiovascular risk in gout
por: Vedder, Daisy, et al.
Publicado: (2020)

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange
por: van Schie, Karin A., et al.
Publicado: (2016)

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
por: Raterman, Hennie G, et al.
Publicado: (2012)

Neutrophil activation identifies patients with active polyarticular gout
por: Vedder, D., et al.
Publicado: (2020)

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial
por: ter Wee, Marieke M, et al.
Publicado: (2017)

Rituximab during the COVID-19 pandemic: time to discuss treatment options with patients
por: Boekel, L, et al.
Publicado: (2022)

Cross-reactive and pre-existing antibodies to therapeutic antibodies—Effects on treatment and immunogenicity
por: van Schie, Karin A, et al.
Publicado: (2015)

An unfavorable body composition is common in early arthritis patients: A case control study
por: Turk, Samina A., et al.
Publicado: (2018)

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
por: Ghalandari, Nafise, et al.
Publicado: (2022)

Favourable effect of a ‘second hit’ after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial
por: Hartman, Linda, et al.
Publicado: (2022)

Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters
por: de Jong, Tamarah D., et al.
Publicado: (2016)

Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial
por: Lucassen, M. J. J., et al.
Publicado: (2021)

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
por: Verstegen, Niels JM, et al.
Publicado: (2022)

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study
por: Bartelds, Geertje M, et al.
Publicado: (2010)

Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate?
por: van Kempen, Z.L.E., et al.
Publicado: (2022)

Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET
por: Verweij, Nicki, et al.
Publicado: (2022)

The Prevalence of Cardiac Diseases in a Contemporary Large Cohort of Dutch Elderly Ankylosing Spondylitis Patients—The CARDAS Study
por: Baniaamam, Milad, et al.
Publicado: (2021)

Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review
por: van Tuyl, Lilian HD, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sc9ss68a5mc7s7d80ebfa699ne